<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362008">
  <stage>Registered</stage>
  <submitdate>26/01/2012</submitdate>
  <approvaldate>1/02/2012</approvaldate>
  <actrnumber>ACTRN12612000143820</actrnumber>
  <trial_identification>
    <studytitle>Under-Recognition of Allergic conjunctivitis in Patients with Allergic Rhinitis</studytitle>
    <scientifictitle>The Effect of Olopatadine Hydrochloride on total ocular symptoms score in Non-allergic conjunctivitis/rhinitis individuals.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>n/a</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Allergic rhinitis</healthcondition>
    <healthcondition>allergic conjunctivitis</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants will be asked about their indirect symptoms of AC (squinting, blinking, frontal headaches or eyelid dermatitis) to assess whether they suffer. Then total Ocular Symptom Score (TOSS) (tearing, itching and eye redness) will be assessed.
Then, one drop of olopatadine hydrochloride to each eye, ONCE ONLY.
Then 5 minutes will pass before assessing TOSS again.</interventions>
    <comparator>Control group will be used to determine if the lubricating effects of the olopatadine eye drops is acting as the relieving factor in the intervention group</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Total ocular symptoms score</outcome>
      <timepoint>pre-administration of olopatadine hydrochloride and then at 5minutes post-administration to detect a change in total ocular symptoms score</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>nil</outcome>
      <timepoint>nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>No allergic conjunctivitis
Over 18 years
Not pregnant
CONFIRMED PARTICIPANTS CANT HAVE AR/AC</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>allergic conjunctivitis/rhinitis</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Patients attending an allergist's outpatients clinic are asked if they would like to participate in this study. if they consent, then they are assessed for symptoms and signs of allergic conjunctivitis. If they do not have any history or symptoms, then they are administered olopatadine hydrochloride to determine if they improved total ocular symptoms scores in patients without allergic conjunctivitis.</concealment>
    <sequence>no randomisation</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>nil</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>13/02/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>A/Prof Peter Smith</primarysponsorname>
    <primarysponsoraddress>Pacific Private Clinic
123 Nerang St
Southport
Q 4215</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>A/Prof Peter Smith</fundingname>
      <fundingaddress>Pacific Private Clinic
123 Nerang St
Southport
Queensland 4215</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress>nil</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Aim:
To determine the most effective way of detecting the incidence of allergic conjunctivitis (AC).
Method:
The first step includes asking patients in an allergy specialist's outpatient clinic about their Total
Ocular Symptom Score (tearing, itching and eye redness), then asking them about indirect
symptoms of AC (squinting, blinking, frontal headaches or eyelid dermatitis), and finally using
an olopatadine challenge to determine if any chronic, undetected symptoms of AC are relieved
and thus suffered.
A control group will be used to determine if the lubricating effects of the olopatadine eye drops
is acting as the relieving factor in the intervention group.</summary>
    <trialwebsite>n/a</trialwebsite>
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>6/02/2012</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A/Prof Peter Smith</name>
      <address>Pacific Private Clinic
Level 5 123 Nerang St
Southport
Queensland 4215</address>
      <phone>+617 5591 5744</phone>
      <fax />
      <email>pksm@mac.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof Peter Smith</name>
      <address>Pacific Private Clinic
Level 5 123 Nerang St
Southport
Queensland 4215</address>
      <phone>+617 5591 5744</phone>
      <fax />
      <email>pksm@mac.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>